Endocrine Abstracts

Background: Pituitary tumours (PT) are generally benign, but they can rarely show an aggressive behaviour, invade surrounding structures and/or grow/recur despite multimodal treatment, making their management extremely challenging. According to the latest guidelines, temozolomide (TMZ) can be an option after failure of standard therapies in aggressive PT, while little data are available on alternative approaches such as peptide receptor radionuclide therapy (PRRT). Herein we r...